Trial Profile

A Phase 1 Open Label Study of the Safety and Pharmacokinetics of SM-03, an anti-CD22 antibody, in Chinese Systemic Lupus Erythematosus Subjects With Active Disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Suciraslimab (Primary)
Indications Systemic lupus erythematosus
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors SinoMab Bioscience Ltd

Most Recent Events

18 Jul 2016 Results published in the Clinical Drug Investigation
21 Dec 2015 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com